Omega Therapeutics

Omega Therapeutics

Edit info

  • Founded: 2017
  • Location: Cambridge, MA
  • Employee range: 51-100
  • Clinical stage: Clin1/Clin2
  • Therapy area: Hepatocellular carcinoma (ODD)
  • Drug types: ONC, HEP, OPH, LNG, DRM
  • Lead product: OTX-2002
  • Funding: 100-500M


omegatherapeutics.com

linkedin.com

job board


Business:

Gene Editing

Drug notes:

OTX-2101 Clin0 NSCLC; 6 undisclosed programs RD/Clin0 SCLC, IPF, liver regeneration, corneal regeneration, alopecia, undisclosed

About:

Omega Therapeutics is developing RNA therapeutics to reprogram the topology of genomic control. Chromatin structure plays an important role in governing gene expression, which becomes perturbed in disease. Omega is addressing aberrant gene expression by engineering programmable mRNA medicines for precision genomic control using their OMEGA Epigenetic Programming platform. Multiplexing enables the targeting of many genomic sites using Omega’s Epigenomic Controllers to regain optimal gene expression to treat or cure diseases. To develop further tools, Omega uses knowledge of the 3D-genomic organization with transcriptomics and machine learning. Currently, they have multiple programs in preclinical studies for regenerative medicine and immunology.

Post a job


© 2025 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com